Date: 07/09/2026

To,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Scrip Code: 539519

Subject: Outcome of Board Meeting of the Company held on today i.e. Monday, September 07th, 2026.

Dear Sir/Madam,

In compliance with Regulations 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the meeting of Board of Directors of the Company held on **today i.e. Monday, September 07, 2026 at its Registered office at Plot No. 2B/1, Ground Floor, Kandivali Cooperative Industrial Estate Ltd., Hindustan Naka, Kandivali (West), Mumbai 400067**. The Board transacted/approved following matters:

1. **Resignation of Statutory Auditor:-**
   The Board took note of the resignation letter dated 07th September, 2026 received from **M/s SSRV & Associates, Chartered Accountants**, [**Firm Registration No. 135901W**], Statutory Auditors of the Company, resigning from the office of Statutory Auditors of the Company with effect from 07th September, 2026.

   The Board considered and accepted the resignation of M/s SSRV & Associates and placed on record its appreciation for the services rendered by the firm during its tenure as Statutory Auditors of the Company.

   The Board further noted that the Company shall obtain the necessary documents, including the resignation letter and such other information as may be required under the applicable provisions of the Companies Act, 2013.

2. **Appointment of New Statutory Auditor**

   The Board considered and approved the appointment of **M/s DEVAM & Associates LLP, Chartered Accountants, [Firm Registration No. 139355W/W100925],** as the Statutory Auditors of the Company in place of M/s SSRV & Associates Statutory Auditors of the company due to resignation, subject to the approval of the members of the Company at the upcoming General Meeting, in accordance with the applicable provisions of the Companies Act, 2013.

The Board noted that the proposed auditor has furnished the requisite consent and eligibility certificate, confirming that the proposed appointment is in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder.

Further, subject to the approval of the members at the ensuing General Meeting, **M/s DEVAM & Associates LLP, Chartered Accountants, [Firm Registration No. 139355W/W100925],** shall be appointed as the Statutory Auditors of the Company for a period of five consecutive years, from the conclusion of the ensuing 46th General Meeting until the conclusion of the 51st Annual General Meeting, in accordance with the applicable provisions of the Companies Act, 2013, subject to approval of members in upcoming general meeting .

3. Considered and approved the Re-Appointment of **Mrs. Khushboo Vasudev (Din: 08415000)** as an Independent Director of the Company for a Second Term of Five Years from December 31, 2026, subject to the shareholders' approval in Coming General Meeting of the company.

4. Considered and discussed the proposal for acquisition of up to 60% equity share capital of **Meyonex Pharmaceuticals Limited**, an unlisted public company, and to authorise preliminary evaluation, due diligence, valuation and negotiations:

   The Board authorised **Mr. CHIRAG DEEPAK DEDHIA, Director**, and **Mr. SACHIN BHANUBHAI MANSETA, Director**, to act as the authorised representatives of the Company, **jointly and/or severally**, for the purpose of exploring, evaluating and progressing the proposed acquisition of up to 60% of the equity share capital of **MEYONEX PHARMACEUTICALS LIMITED**, having **CIN - U74120MH2015PLC261024**.

   Accordingly, **Mr. CHIRAG DEEPAK DEDHIA** and **Mr. SACHIN BHANUBHAI MANSETA** be and are hereby authorised to:

   i. Initiate and conduct preliminary discussions with the existing shareholders, promoters and/or management of Meyonex Pharmaceuticals Limited in relation to the proposed acquisition;
   ii. Discuss and negotiate the broad commercial, financial and legal terms of the proposed transaction, including proposed percentage of acquisition, valuation, purchase consideration, payment terms, transaction structure, representations and warranties, indemnities, conditions precedent, governance arrangements and other related matters;
   iii. Obtain and review relevant financial, legal, technical, regulatory, operational, commercial and other information and documents from the Target Company and its existing shareholders/management;
   iv. Identify, appoint and engage appropriate independent Registered Valuers/valuation professionals, legal advisors, financial advisors, tax consultants, technical consultants, pharmaceutical/manufacturing experts and other professional advisors for the purpose of valuation and due diligence of the Target Company;

v. Coordinate and supervise the financial, tax, legal, secretarial, regulatory, technical, pharmaceutical, manufacturing, quality, GMP/cGMP, environmental, commercial, operational, intellectual property and other due diligence processes;
vi. Execute, on behalf of the Company, appropriate confidentiality agreements, non-disclosure agreements, letters of intent, term sheets or other **non-binding documents**, wherever considered necessary and appropriate for progressing the evaluation of the proposed transaction, subject to applicable law and the Company's internal policies;
vii. Liaise and correspond with the Target Company, its shareholders, management, professional advisors, valuers, consultants and other relevant persons in connection with the proposed transaction;
viii. Obtain such further information, clarifications, reports and professional opinions as may be necessary for placing the final proposal before the Board and/or the appropriate Committee(s) of the Company;
ix. Undertake all such other preliminary and incidental acts, deeds, matters and things as may be necessary or desirable for evaluating and progressing the proposed transaction.

5. Considered and approved the proposal for specific limit for Material Related Party Transactions/, Related Party Transaction, u/s 188 of Companies Act 2013, recommend to the shareholders' approval in Coming General Meeting of the company.

6. Considered and took on record the Secretarial Auditor Report received from M/s. Brajesh Gupta & Co., Practicing Company Secretaries for the F.Y 2025-2026.

7. Took note on status of Statutory Registers maintained under Companies Act, 2013.

8. Took on record performance evaluation of Auditors done by Audit Committee.

9. Approved and adopted the Board Report, Corporate Governance Report, Management Discussion and Analysis Report and other report and certificate for the financial year ended March 31, 2026.

10. Approved and fixed Day, Date, Time, calendar of events of 46th Annual General Meeting of the Company along with the Notice of 46th Annual General Meeting.

11. The Board fixed the date for Book Closure for 46th AGM of the Register of Members and Transfer Books of the company from 24th September 2026 to 30th September, 2026.

12. The Board appointed Mr. Brajesh Gupta, Practicing Company Secretary proprietor of M/s. Brajesh Gupta & Co as Scrutinizer for conducting E-voting process for Annual General Meeting of the Company.

13. The Board of Director authorized the Managing Director or Company Secretary of the Company to issue Notice of 46th AGM and be responsible for conduct AGM and the entire E-voting process in fair and transparent manner.

The aforesaid Board Meeting commenced at 5.45 P.M. and concluded at 7:13 P.M.

Please take the same on your record and acknowledge the receipt of the same.

Thanking You,
Yours Faithfully

For Tavexia Lifecare Limited
(Formerly Sattva Sukun Lifecare)

Poonam Rani

Digitally signed by Poonam Rani
Date: 2026.09.07 19:16:10 +05'30'

Poonam Rani
Company Secretary

Annexure-I

Resignation of M/s. SSRV and Associates, Chartered Accountants, (Firm Registration Number: 135901W), Information as required under Regulation 30 – Part A Schedule III of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided below:

Sno	Particulars	Details
1	Reason for Change ~~viz. Appointment ,~~ ~~reappointment~~, resignation~~, removal ,~~ ~~death or otherwise~~	The Board of Directors have at their meeting held today i.e September 07, 2026, approved the Resignation of M/s. SSRV and Associates, Chartered Accountants, (Firm Registration Number: 135901W), as the Statutory Auditors of the Company,
2	Date of ~~appointment / re-appointment/~~ cessation (as applicable) ~~& term of appointment/reappointment~~	**Date of cessation** – 07th September,2026
3	Brief Profile (In case of appointment)	Not applicable
4	Disclosure of relationships between Directors (in case of appointment of Director)	Not applicable
5	Information required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated 20 June 2018.	Not applicable

Annexure-II

TAVEXIA LIFECARE LIMITED

(FORMERLY SATTVA SUKUN LIFECARE LIMITED)

CIN: L27509MH1980PLC329224

Appointment of M/s DEVAM & Associates LLP, Chartered Accountants, [Firm Registration No. 139355W/W100925],

Information as required under Regulation 30 – Part A Schedule III of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided below:

Sno	Particulars	Details
1	Reason for Change viz. Appointment , ~~reappointment~~, ~~resignation, removal , death or otherwise~~	The Board of Directors have at their meeting held today i.e September 07, 2026, approved the appointment of **M/s DEVAM & Associates LLP, Chartered Accountants, [Firm Registration No. 139355W/W100925],** as the Statutory Auditors of the Company, subject to approval of members of the Company at the ensuing Annual General Meeting (AGM) and for the term as mentioned in the table below
2	Date of appointment / re-appointment/ ~~cessation (as applicable) & term of appointment/reappointment~~	**Date of appointment**- September 07, 2026, subject to approval of the members of the Company at the ensuing AGM of the Company. **Term of appointment**- 1st term of five consecutive years commencing from the financial year 2026-27 till the financial year 2030-31
3	Brief Profile (In case of appointment)	M/s DEVAM & Associates LLP, Chartered Accountants, bearing Firm Registration No. 139355W/W100925, is a professionally managed Chartered Accountancy firm based in Mumbai and registered with the Institute of Chartered Accountants of India (ICAI). The firm provides a comprehensive range of professional services including Audit and Assurance, Direct and Indirect Taxation, Risk Assessment and Advisory, Forensic Audit, Business Advisory, Company Law and Secretarial Compliance, Virtual CFO services, RERA Compliance, Business Restructuring and Tax Planning. The firm has experience in providing professional services to businesses across various sectors and combines experienced professionals with a focus on providing practical, timely and customised solutions to its clients. The firm has professionals having expertise in areas including Statutory Audit, Taxation, GST, Forensic Audit, Transfer Pricing, Financial and Strategic Planning, FEMA and allied laws.
4	Disclosure of relationships between Directors (in case of appointment of Director)	Not applicable
5	Information required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated 20 June 2018.	Not applicable

TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

ANNEXURE 'II'

The brief profile of Mrs. Khushboo Vasudev (Din: 08415000) as per requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	**Particulars**	**Details**
1	Name of the Director	**Mrs. Khushboo Vasudev (Din: 08415000)**
2	Reasons of change viz. ~~appointment,~~ reappointment, ~~resignation, removal, death or otherwise~~	Reappointment
3	Date of ~~appointment~~ / reappointment /~~cessation (as applicable) & term of appointment / reappointment;~~	Re-appointment as Independent Director for 2nd Term a period of five (05) years subject to the approval of the Members
4	Brief profile (in case of appointment);	More than Ten Year of experience in Corporate Law, Corporate Management and Compliance
5	Disclosure of relationship between Directors (in case of appointment of a Director)	NA

Disclosure regarding Preposed Acquisition of shares of MEYONEX PHARMACEUTICALS

LIMITED, pursuant to Regulation 30 of the SEBI Listing Regulations

Particulars	Details
Name of the target entity	MEYONEX PHARMACEUTICALS LIMITED
Authorised Capital (Rs) **Paid up Capital (Rs)**	20,00,00,000/- 13,99,81,200/-
Registered Address	PLOT NO C - 13 MIDC TARAPUR PALGHAR, Thane, PALGHAR, Maharashtra, India,401506
Industry to which the entity being acquired belongs	Pharmaceuticals